Clinical Development
Sponsored observational pilots build evidence and workflow proof now. RetinaTek's planned first 510(k) is RT-Focus, followed by later condition-specific development of RT-TRACE for adult and pediatric concussion recovery.
The clinical challenge after concussion is not only whether an injury occurred. It is whether the person is recovering as expected. RT-TRACE remains investigational, and clinical recovery-monitoring claims require appropriate validation and clearance.
RetinaTek separates current research use, planned commercial cognitive-performance assessment, and future regulated clinical claims. Each pathway has a different purpose, evidence requirement, and claims boundary.
RetinaTek can support governed, clinic-delivered observational work focused on objective neurocognitive endpoints, longitudinal protocols, usability, workflow feasibility, utilization, and data quality.
Use cases
RetinaTek has completed FDA Q-Submission engagement. The planned first 510(k) is RT-Focus, a computerized cognitive assessment aid, with predicate fit and the evidence plan being finalized with regulatory advisors.
Evidence and product priorities
Concussion recovery remains RetinaTek's commercial market focus. After the first general assessment clearance, a later condition-specific program would be required before RT-TRACE can carry concussion recovery-monitoring or decision-support claims.
Use cases after appropriate validation and clearance
Diagnosis matters, but it is only the starting point. After concussion or mild TBI, clinicians and patients face a more difficult question: is recovery progressing as expected?
Symptoms can be subjective. Standard imaging is often normal. Brief cognitive screens may miss subtle deficits or fail to show whether a patient is improving, plateauing, or worsening over time. Clinical decisions often depend on episodic visits and incomplete information.
RETINA's future clinical-development focus is longitudinal: brief, repeatable, task-standardized measurement that may help characterize recovery trajectory after appropriate validation and clearance.
Objective repeat testing may help show whether performance is moving in the expected direction.
Longitudinal measurement may help identify patients whose recovery trajectory is not progressing as expected.
Repeatable cognitive-performance measures may support treatment-response tracking in future validated use cases after appropriate validation and clearance.
Objective performance trends may help inform when additional evaluation, specialty care, imaging, or biomarkers are most appropriate.
RETINA is brief, task-standardized, and designed to measure performance under controlled cognitive demand. That makes the platform well suited to tracking change over time rather than producing only a one-time snapshot.
Designed for low-burden, repeatable testing in research and supervised clinical workflows.
The same cognitive demands can be presented consistently across visits.
Eye movements, pupil dynamics, manual responses, and task timing provide complementary views of performance.
Longitudinal testing can help characterize whether performance is improving, stable, or declining.
Automated quality checks help determine whether results are usable and interpretable.
Headset-based administration supports use outside specialized neuropsychology or imaging environments.
After validation and regulatory clearance for the intended use, objective recovery tracking may help clinicians allocate care more efficiently. Patients whose performance trajectory is not improving as expected may warrant additional evaluation, specialty referral, imaging, biomarkers, or intensified treatment. Patients whose recovery trajectory appears to be progressing appropriately may avoid unnecessary escalation.
RETINA is not intended to replace clinician judgment, imaging, blood biomarkers, or specialist evaluation. The goal is to provide a repeatable functional measurement layer that complements those tools and helps clinicians make better longitudinal decisions.
After validation and clearance for the intended use, help identify patients whose recovery trajectory suggests elevated need.
After validation and clearance for the intended use, support decisions about whether care should continue, intensify, or step down.
After appropriate validation and clearance, provide objective recovery information that may complement clinical judgment.
Potentially avoid additional high-burden evaluation when recovery is proceeding appropriately.
Provide repeatable functional performance data alongside biological and structural tools.
RetinaTek's roadmap is staged to create value while maintaining clear claims boundaries and building the evidence required for future regulated indications.
Support research and clinical-development studies using task-evoked multimodal neurocognitive endpoints.
Pursue NIH applications, funding, and partnerships for adult and pediatric concussion/mTBI validation programs.
Define the device/software configuration, administration workflow, scoring outputs, documentation, and data-handling processes for future clinical studies.
Advance documentation, usability, cybersecurity, risk management, data integrity, and quality controls appropriate for regulated development.
Use completed Q-Submission feedback to finalize intended use, predicate fit, output scope, evidence requirements, and submission planning with regulatory advisors.
Evaluate performance in intended-use populations with pre-specified endpoints, repeatability, usability, safety, and data-quality measures.
Pursue a narrowly defined first clinical claim, then expand into adjacent monitoring use cases after evidence and clearance support additional indications.
Future regulated claims require more than promising science. RetinaTek's clinical-development work must demonstrate that the platform is repeatable, usable, interpretable, and clinically meaningful in the intended-use population.
Intended-use population
Adult and pediatric subgroup considerations
Repeatability and reliability
Reliable change over time
Sensitivity to recovery trajectory
Relationship to clinician assessment and accepted benchmarks
Treatment-response tracking potential
Usability and tolerability
Data quality and interpretability
Safety and risk controls
Workflow feasibility
Clear claims and labeling
RetinaTek's goal is to provide an objective functional measurement layer that complements existing tools and supports better longitudinal decisions.
RetinaTek has completed FDA Q-Submission engagement, and that feedback informs its active 510(k) strategy. The planned first 510(k) is RT-Focus, a computerized cognitive assessment aid. RT-TRACE remains investigational, and concussion-specific claims require appropriate validation and regulatory clearance.
RetinaTek is engaging concussion programs, research groups, and sponsors interested in governed observational pilots, longitudinal neurocognitive measurement, and real-world workflow proof.